🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Chemotherapy

    International Peace Maternity and Child Health Hospital

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  2. Chemotherapy

    United Therapeutics Europe Ltd

    Transitional Cell Carcinoma of Ureter

    phase 3 small molecule active

    1 trial

  3. Chestnut Bloomington Outpatient (CBOP)

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 other completed

    1 trial

  4. Cholecalciferol (Vitamin D/Vigantol oil)

    United Therapeutics Europe Ltd

    Respiratory Tract Infections

    phase 3 other completed

    1 trial

  5. Cholic Acid

    Mirum Pharmaceuticals International B.V.

    Bile Acid Synthesis Defect

    phase 3 small molecule completed

    1 trial

  6. Cholic Acids

    Mirum Pharmaceuticals International B.V.

    Infantile Refsum's Disease

    phase 3 small molecule completed

    1 trial

  7. Cholic acid

    Mirum Pharmaceuticals International B.V.

    Inborn Errors of Bile Acid Synthesis

    phase 3 small molecule completed

    1 trial

  8. Choline Chloride for Injection

    Protara Therapeutics

    Choline Deficiency

    phase 3 small molecule active

    1 trial

  9. Chronocort®

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    5 trials

  10. Cilta-cel

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. Cimzia 200 mg solution for injection in pre-filled syringe, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adult women with recurrent implantation failures (RIF)

    phase 3 small molecule active

    1 trial

  12. Cinryze®

    Takeda

    Acute Antibody-Mediated Rejection (AMR)

    phase 3 mab terminated

    1 trial

  13. Ciprofloxacin (BAYQ3939) dry powder for inhalation

    Bayer HealthCare AG

    Bronchiectasis

    phase 3 small molecule completed

    1 trial

  14. Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Squamous Cell Carcinoma of Head and Neck

    phase 3 small molecule active

    1 trial

  15. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  16. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

  17. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  18. Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion

    Taiho Pharma Netherlands B.V.

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 3 small molecule active

    1 trial

  19. Class I or III Antiarrhythmic Medications

    Rhythm Pharmaceuticals Netherlands B.V.

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  20. Clazakizumab

    CSL Behring GmbH

    Antibody-mediated Rejection

    phase 3 mab terminated

    1 trial

  21. Clemizole HCl

    Harmony Biosciences Holdings

    Dravet Syndrome

    phase 3 small molecule active

    1 trial

  22. Clemizole HCl

    Harmony Biosciences Holdings

    Lennox Gastaut Syndrome

    phase 3 small molecule active

    1 trial

  23. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

  24. Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis

    Alphapharm Pty Ltd

    Chronic stable plaque psoriasis

    phase 3 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources